Last reviewed · How we verify
ChimeriVax-WN02 Low Dose
ChimeriVax-WN02 Low Dose is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development for Prevention of dengue fever.
ChimeriVax-WN02 Low Dose is a vaccine that targets the dengue virus.
ChimeriVax-WN02 Low Dose is a vaccine that targets the dengue virus. Used for Prevention of dengue fever.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
Sanofi Pasteur, a Sanofi Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ChimeriVax-WN02 Low Dose |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
It works by inducing an immune response against the dengue virus, providing protection against dengue fever. This is achieved through the use of a live, attenuated dengue virus strain. The vaccine is designed to stimulate the body's immune system to produce antibodies and immune cells that can recognize and fight the dengue virus.
Approved indications
- Prevention of dengue fever
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults (PHASE2)
- Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChimeriVax-WN02 Low Dose CI brief — competitive landscape report
- ChimeriVax-WN02 Low Dose updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about ChimeriVax-WN02 Low Dose
What is ChimeriVax-WN02 Low Dose?
How does ChimeriVax-WN02 Low Dose work?
What is ChimeriVax-WN02 Low Dose used for?
Who makes ChimeriVax-WN02 Low Dose?
What drug class is ChimeriVax-WN02 Low Dose in?
What development phase is ChimeriVax-WN02 Low Dose in?
What are the side effects of ChimeriVax-WN02 Low Dose?
Related
- Drug class: All vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Prevention of dengue fever
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing